Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
STAT3-targeted Drugs R&D Service

STAT3-targeted Drugs R&D Service

Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

STAT3-targeted Drugs R&D Service

STAT3, a member of the STAT family, is a latent transcription factor that is activated in response to various cytokines, growth factors, and oncogene signals. STAT3 is constitutively activated in various human cancers, and its activation is frequently associated with poor prognosis. As a transcription factor, STAT3 regulates a set of genes implicated in cancer cell survival, proliferation, angiogenesis, invasion, metastasis, drug resistance, and immune evasion. Medicilon provides STAT3 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.

Download
Introduction of STAT3
Structure of STAT3
Signal Pathway of STAT3
STAT3 Inhibitors
Medicilon Case Study
Medicilon Assisted Projects
Summary and Outlook
Service Cases
Relevant laboratories
prev page next page
  • RAD
  • FCM
  • IVIS-Lumina-III-In-Vivo-Imaging-System
  • high-speed centrifuge
  • PCR
  • Microplate reader
Return